A Novel Genetic Mechanism of Caplacizumab Resistance in iTTP – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Mari Thomas et al., adding:
“Caplacizumab Resistance in Immune Thrombotic Thrombocytopenic Purpura (iTTP) Associated with VWF A1 Domain Missense Variant
This landmark first report describes caplacizumab resistance in an iTTP patient caused by a VWF A1 domain missense variant (P1266L) that impairs drug binding, revealing a novel genetic mechanism of treatment failure beyond premature therapy discontinuation.”
Title: Caplacizumab resistance in immune thrombotic thrombocytopenic purpura is associated with a von Willebrand factor A1 domain missense variant
Authors: Mari Thomas, Imogen Buckle, Adela Constantinescu-Bercu, Rens De Groot, Sabina McCann, Marie Scully
Read the Full Article on JTH
Other articles about Journal of Thrombosis and Haemostasis
-
Oct 14, 2026, 20:36How Does Inflammation Reshape Red Blood Cell Production? – ASH
-
Oct 14, 2026, 20:30Marilena Vrana: Putting Faces to the Chain – Donors and Patients Connect in Milan for IPAW 2026
-
Oct 14, 2026, 20:25Asim Alam: Hillsborough County and Partners Demonstrate Drone-Based Emergency Blood Delivery
-
Oct 14, 2026, 20:19Zahid Khanzada: 3rd Position in the Hematology Quiz at PCUH
-
Oct 14, 2026, 20:14Samiul Bashir: The 47th Recognized System in Transfusion Medicine
-
Oct 14, 2026, 20:06Mavis Agnes Kisakye: Petition Advocating for Enhanced Haemophilia Care Presented to EALA Parliament
-
Oct 14, 2026, 20:03Sheharyar Raza: What Are Ways AI and ML Are Impacting How We Collect and Transfuse Blood?
-
Oct 14, 2026, 19:58Alessandro Lucchesi: Three Minutes of RiseMPN 2025
-
Oct 14, 2026, 19:55Talha Waseem: HbA1c – What Does Its Name Actually Mean?